WASHINGTON (dpa-AFX) - St. Jude Medical Inc. (STJ) Tuesday said its Allure Quadra Cardiac Resynchronization Therapy Pacemaker or CRT-P received CE Mark approval and subsequently is being launched in Europe. The Allure Quadra CRT-P brings the quadripolar lead technology to the pacemaker market for the first time and offers more pacing options to deliver higher success rates, said the company.
Quadripolar leads allow for increased implant efficiencies, which clinical data indicates can result in fewer surgical revisions.
Commenting on the development, Dr. Amir Zaidi, consultant cardiologist and devices lead at Manchester Royal Infirmary, England said, ' Adding quadripolar technology to the CRT-P platform moves us forward in the treatment of heart failure and allows us to expand the proven clinical benefits to a new patient population...The new features and additional pacing options allow for optimal lead placement and provide the patient greater opportunities to respond to therapy, while reducing the need for re-intervention.'
The company added that its quadripolar technology allows for additional pacing configurations that provide physicians with options not available on traditional bipolar systems and that these additional options help manage common pacing complications without exposing the patient to additional surgeries for lead repositioning.
Additionally, the Allure CRT-P device is said to imrove HF management with timely access to vital diagnostic data including CorVue Impedance Monitoring for earlier insight into HF progression, and Direct Trend Reports for a simplified look at all device data.
Copyright(c) 2013 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2013 AFX News
